Mereo BioPharma Group (LTS:0A9G) Current Accrued Expense : $2.23 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group Current Accrued Expense?

Mereo BioPharma Group's Current Accrued Expense for the quarter that ended in Mar. 2025 was $2.23 Mil.

Mereo BioPharma Group's quarterly Current Accrued Expense increased from Sep. 2024 ($1.61 Mil) to Dec. 2024 ($1.80 Mil) and increased from Dec. 2024 ($1.80 Mil) to Mar. 2025 ($2.23 Mil).

Mereo BioPharma Group's annual Current Accrued Expense declined from Dec. 2022 ($3.57 Mil) to Dec. 2023 ($3.46 Mil) and declined from Dec. 2023 ($3.46 Mil) to Dec. 2024 ($1.80 Mil).

Mereo BioPharma Group Current Accrued Expense Historical Data

The historical data trend for Mereo BioPharma Group's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Current Accrued Expense Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

5.69

5.16

3.57

3.46

1.80

Mereo BioPharma Group Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															2.11	2.60	1.61	1.80	2.23

Mereo BioPharma Group Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Mereo BioPharma Group Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

MREO:USA MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines